Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 11Completed 2Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Non-Small Cell Lung Cancer Metastatic 1Neoplasms 1Neoplasm Metastasis 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 219pembrolizumab 199Magnetic Resonance Spectroscopy 197Carboplatin 173Cisplatin 139Biopsy 133Nivolumab 129Paclitaxel 115Radiotherapy 111Cyclophosphamide 111Gemcitabine 104durvalumab 90Dexamethasone 90atezolizumab 76Radiation 72Rituximab 71Lenalidomide 69Pemetrexed 66Doxorubicin 65Bevacizumab 65Docetaxel 62Ipilimumab 58Etoposide 57olaparib 55Fluorouracil 52venetoclax 50Taxes 50Radiosurgery 50Oxaliplatin 50Prednisone 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × patritumab deruxtecan × 90 days × Clear all
NCT04619004 2026-05-14

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

Daiichi Sankyo

Phase 2 Active not recruiting
277 enrolled 16 charts
Thoracic

Non-Small Cell Lung Cancer Metastatic

NCT03260491 2026-03-05

U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer

Daiichi Sankyo

Phase 1 Active not recruiting
312 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡